Andres Jan Schrader
Overview
Explore the profile of Andres Jan Schrader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steike D, Troschel F, Roers J, Siats J, Kittel C, Pepper N, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410023
In our study, the post-radiotherapy quality of life of prostate cancer patients who previously underwent transurethral resection of the prostate (TURP) is compared to those who had thulium laser enucleation...
2.
Wustmann N, Humberg V, Vieler J, Seitzer K, von Ruden S, Juratli M, et al.
Lab Invest
. 2024 Sep;
104(10):102142.
PMID: 39307310
Circulating tumor cells and liquid biopsy-based biomarkers might one day play a crucial role in the treatment decision process for patients of several cancer entities. However, clinical studies on liquid...
3.
Silberg M, Krabbe L, Bogemann M, Schrader A, Tully K, Schlack K
Clin Genitourin Cancer
. 2024 Aug;
22(5):102164.
PMID: 39153900
Background: Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents...
4.
Lange S, Kuntze A, Wustmann N, Reckers T, Humberg V, Dirks W, et al.
Biol Res
. 2024 May;
57(1):21.
PMID: 38704600
Background: Research on prostate cancer is mostly performed using cell lines derived from metastatic disease, not reflecting stages of tumor initiation or early progression. Establishment of cancer cell lines derived...
5.
Queissert F, Schrader A
Aktuelle Urol
. 2024 Apr;
55(4):302-307.
PMID: 38653468
Low compliance is not an independent disease but a severe manifestation resulting from various disorders of the storage and excretory function of the bladder. Reduced distensibility of the detrusor muscle...
6.
Abbas M, Heitplatz B, Bernemann C, Boegemann M, Trautmann M, Schrader A, et al.
Oncol Lett
. 2023 Nov;
26(6):527.
PMID: 38020299
In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been...
7.
Mikuteit M, Zschabitz S, Stohr C, Herrmann E, Polifka I, Agaimy A, et al.
Urol Int
. 2023 Jun;
107(7):713-722.
PMID: 37348477
Introduction: Growth arrest-specific protein 6 (Gas 6) is a ligand that plays a role in proliferation and migration of cells. For several tumor entities, high levels of Gas 6 are...
8.
Wustmann N, Seitzer K, Humberg V, Vieler J, Grundmann N, Steinestel J, et al.
Biomark Res
. 2023 Apr;
11(1):37.
PMID: 37016463
Background: Androgen receptor (AR) splice variants (AR-Vs) have been discussed as a biomarker in prostate cancer (PC). However, some reports question the predictive property of AR-Vs. From a mechanistic perspective,...
9.
Zschabitz S, Mikuteit M, Stohr C, Herrmann E, Polifka I, Agaimy A, et al.
Discov Oncol
. 2022 Sep;
13(1):90.
PMID: 36136143
Background: Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and...
10.
Mondorf Y, Mikuteit M, Ivanyi P, Stohr C, Herrmann E, Polifka I, et al.
Urol Int
. 2022 Jun;
106(11):1168-1176.
PMID: 35654002
Introduction: Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor...